Dinutuximab Beta-Targeted Immunotherapy Kills Pancreatic Beta Cell Tumors

Ayşe Karatug Kacar (✉ akaratug@istanbul.edu.tr)

Istanbul University

Zelal Adıgüzel

Koç University, Basic Medical Sciences

Research Article

Keywords: Insulinoma, INS-1 cell line, Dinutuximab beta, Cell Death, Cytotoxicity

Posted Date: February 24th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1372329/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Dinutuximab beta is the first monoclonal antibody that used for the treatment of neuroblastoma. The aim of this study is to investigate the effects of Dinutuximab beta, whose effect is unknown in pancreatic beta cell tumor, based on the similarity between pancreatic beta cells and neurons. We have used insulinoma INS-1 cells. Dinutuximab beta (Qarziba®) which presented by EUSA Pharma was used for the experiments. The cell cytotoxicity was induced by STZ. Dinutuximab beta was administered to the cells following STZ administration and before STZ administration. The cell viability with WST-1 assay, reactive oxygen species by using dichlorofluorescein diacetate were measured. The cells were marked with DAPI to indicate apoptotic markers with confocal microscope. GLUT2, IR, Ins1 and Ins2 expression levels were analyzed with q-RT-PCR. The INS-1 cells proliferated with administration of Dinutuximab beta alone. The result of Dinutuximab beta administered following STZ administration, resulted in more cell death, increased ROS levels, GLUT2, Ins1, Ins2 gene expression levels and decreased IR gene expression levels than Dinutuximab beta administered before STZ administration. After Dinutuximab beta was administered to the cells following STZ administration, the cells predominantly died via apoptosis showing cytoplasmic condensation and DNA fragmentation after 24 and 48 hours. As a result, Dinutuximab beta can show its effect after occurring toxicity. Time-dependent cell death increases as a result of administration of Dinutuximab beta after toxicity induced by STZ in insulinoma cells. Its use as a chemotherapeutic agent in tumor treatment should be supported by in vivo studies.

Introduction

Insulinoma is a gastroenteropancreatic neuroendocrine tumor arising from the uncontrolled proliferation of pancreatic β cells. The majority (90%) of insulinomas are benign. However, it may cause recurrent hypoglycemia as a result of excessive insulin secretion. This makes insulinoma potentially fatal [1, 2]. In addition, incomplete resection after surgery may cause symptoms to persist [2]. The most used insulin-secreting cell lines are beta TC, HIT, RIN, MIN6, and INS-1 cells [3]. INS-1 displays many important characteristics of pancreatic beta cells with its high insulin content in response to glucose [4]. In our study, INS-1 Insulinoma cells were used.

Dinutuximab beta is a disialoganglioside 2 (GD2) targeted monoclonal antibody that is overexpressed in neuroblastoma cells [5]. It was approved by the European Medicines Agency in 2017 for the treatment of high-risk neuroblastoma in patients with minimal response to chemotherapy, stem cell transplantation, age 12 months and older, and relapses [6]. The European Neuroblastoma group of the International Society of Pediatric Oncology currently recommends Dinutuximab beta administered as a continuous intravenous infusion at 10 mg/m² daily for ten days as standard care for patients with high-risk neuroblastoma [7].

Immunotherapy has recently resulted in an increase in survival rates for various adult cancers [8]. The increased survival of patients with high-risk neuroblastoma as a result of the application of anti-GD2

therapy in addition to standard care demonstrates the potential and importance of immunotherapy in pediatric oncology [9].

Dinutuximab-induced cytotoxicity is thought to be mediated mainly by natural killer (NK) cells and neutrophils [10, 11]. Without immunotherapy, T cells cannot recognize neuroblastoma due to low expression of Major Histocompatibility Complexes (MHC-I), and the activity of natural killer (NK) cells is inhibited due to low expression of activating ligands. Immune regulatory mediators in the tumor microenvironment (TME), mesenchymal stem cells (MSC), and myeloid-derived suppressor cells (MDSC) inhibit NK and T cell function. Various targets can be used for immunotherapy [12].

Streptozotocin (STZ) is a toxic glucose analog that can enter pancreatic β cells via glucose transporter 2 (GLUT2). It is widely used to establish experimental diabetes *in vivo* studies [13]. This model is mainly used to investigate the cytotoxicity of pancreatic β cells after various treatments or to establish hyperglycemia for long-term studies [14, 15]. Oxidative stress and DNA alkylation have been implicated as major mechanisms for STZ-induced pancreatic β -cell injury [16, 17].

In our *in vitro* study, it was observed that the cells proliferated as a result of DB administration to insulinoma INS-1 cells. Based on the knowledge that this monoclonal immunotherapy drug is effective in cytotoxic conditions, STZ was first applied to the cells. Cell death was performed by applying DB to the cells in which cytotoxicity was created with STZ. By determining which type of this cell death is, its effect on insulin secretion and reactive oxygen species at doses causing cell death was investigated. In addition, the protein and gene levels of some channel proteins thought to be related to the insulin mechanism were analyzed. In this context, the effect of DB monoclonal antibody in the treatment of insulinoma was investigated.

Methods

Materials

HEPES (H3375), trypsin-EDTA (T4049), sodium pyruvate (S8636), 2,7-dichlorofluorescein diacetate (D6883) from Sigma Aldrich (St. Louis, Mo.); RPMI 1640 (21875-034), Penicillin-Streptomycin (10378016) and Fetal Bovine Serum (26140079) from Gibco (Paisley, Scotland); Bradford Protein Assay (#500-0006), 2-mercaptoethanol (#1610710), iScript™-cDNA-Synthesis kit from Biorad (Hercules, California); NucleoSpin® (# 740955.50) RNA II (Macherey-Nagel, Düren, Germany); DNaseI (Macherey-Nagel, Düren, Germany); Applied Biosystems SYBR™ Green PCR supermix (# 4364344) (Applied Biosystems, Waltham, Massachusetts, United States); Phosphatase-Proteinase Inhibitor (A32959) from Thermo Scientific (Rockford, IL); DAPI (28718-90-3) from Merck (Kenilworth, New Jersey), WST1 (11644807001) from Roche was purchased.

Cell culture

Rat insulinoma INS-1 cell line was a generous gift from Prof. Dr. Claes B. Wollheim (University Medical Center, Geneva). INS-1 cells were cultured in 5% CO₂/95% humidified air at 37°C in RPMI 1640 containing 10% fetal bovine serum, 100 IU/ml penicillin and 100 µg/ml streptomycin, 10 mM HEPES, 50 µM 2-mercaptoethanol, 1 mM sodium pyruvate. 0.25% trypsin-EDTA was used for the passage of INS-1 cells. After that, the cells were incubated in an incubator with 5% CO₂/95% humidified air at 37°C for 24 hours.

The formation of pancreatic beta cell cytotoxicity

The pancreatic beta cell cytotoxicity induced by STZ. STZ dissolved in citrate buffer (CB) (0,1M, pH 4,6). The different doses of STZ were applied to insulinoma INS-1 cells by WST1 analysis. IC₅₀ value was obtained as a result of multiple repetitions. IC₅₀ value was found as 3.2373 mM after 2 hours of STZ incubation with cells.

Cell Viability Analysis

5x10⁴ cells/wells were plated on 96-well plates for WST-1 assay. It was solved STZ in citrate buffer (CB), DB in the medium (C). Citrate buffer and the medium was given to cells as the control group. The cells were incubated for 2h for STZ and CB; 24, 48, and 72h for DB and C; 2h + 24, 48, and 72h for STZ + DB and CB + C; 24, 48, and 72h + 2h for DB + STZ and C + CB. After that, the medium was removed. 100 µl/well fresh medium and 10 µl/well WST-1 were added in wells. The cells were incubated in 5% CO₂/95% humidified air at 37°C for 3 h. After incubation WST-1 results were analyzed by a spectrophotometer. The control value was considered as 100%. The cell viability rate was calculated according to the control.

Cell Death Detection Analysis

2x10⁵ cells/wells were seeded on coverslips and incubated for 24 h in CO₂%5 incubators at 37 °C. On the next day, cells were treated with a certain dose of the experimental setup and waited for incubation times. After the incubations, cells were fixed with 4% paraformaldehyde for 15m at room temperature. After that, the cells were washed with PBS and stored at + 4 until studied. It was stained with a mounting medium containing DAPI for condensation and fragmentation. Images were taken using a confocal microscope (Leica, Light Sheed, DMI8).

ROS Assay

5x10⁴ cells/wells were plated on 96-well plates and then the cells incubated with 5% CO₂ at 37°C. The determined doses were applied to the cells for incubation times. 2,7-dichlorofluorescein diacetate (DCFA) was used to measure for intracellular reactive oxygen species (ROS). INS-1 cells were incubated for half an hour with 10 mM DCFA. Cells were analyzed on a fluorescent ELISA plate reader. The control group values were accepted as 100%. The values of the experimental group were calculated according to the control group.

Gene Expression Analysis

- RNA isolation and cDNA Synthesis

Total RNA was isolated from the cell pellets with NucleoSpin® RNA II according to the kit protocol. To digest genomic DNA contamination, RNA samples were treated with DNaseI. RNA concentration and quality were determined with a Nanodrop spectrophotometer. Total RNA samples using 1 mg total RNA were reverse-transcribed using the iScript™-cDNA-Synthesis kit, according to the manufacturer's protocol.

- Real time PCR

Real-time PCR was performed with Applied Biosystems SYBR™ Green PCR supermix using Quantstudio 7 real-time PCR device. The primer as follows: Glut2; forward: GCTGGAAGAAGCGTATCAGG, reverse: AATCCTGATTGCCCAGAATG; IR; forward: CCTACTGCTATGGGCTCCG, reverse: AGGATCTGCAGATGGCCCTC, Ins-1; forward: GGGGAACGTGGTTTCTTCTAC, reverse: CCAGTTGGTAGAGGGAGCAG, Ins-2; forward: CAGCACCTTTGTGGTTCTCA, reverse: CACCTCCAGTGCCAAGGT, Beta Actin; forward: 5'-GGTCGGTGTGAACGGATTTGG-3, reverse: 5'-ATGTAGGCCATGAGGTCCACC-3. PCR reactions were set in 12.5 µl and melting curve analyses were done. Ct values were converted into arbitrary units using the $\Delta\Delta C_t$ method. For all the samples primer dimers were checked and confirmed that there were no primer dimers.

Statistical Analysis

Multiple comparisons were made with the ANOVA variance analysis test and non-parametric Tukey's test using GraphPad Prism 5 computer software. The results were expressed by $\pm$ S.E.M. The value of $p < 0.05$ was considered to be statistically significant. All experiments were repeated for triplicate on different days.

Results

Dinutuximab beta application to toxicity induced INS-1 cells reduces cell viability

Cell proliferation increased over time when DB was administered alone. After calculating the IC50 value of STZ, this dose was applied to INS-1 cells before and after being given DB. Cell viability further decreased over time in the group treated with STZ before DB according to the group given STZ after DB (Fig. 1).

Apoptotic cell death occurs with Dinutuximab beta application to toxicity induced INS-1 cells Apoptotic cell death occurs in the group treated with DB for 24 and 48 hours after STZ application. More apoptotic cell death was observed at 24 h than at 48 h. Although cell death was much higher at 72 hours, this death was not apoptotic cell death. No significant cell death was observed at 24, 48, and 72 hours in the STZ-treated group after DB administration (Fig. 2).

ROS increases with Dinutuximab beta application to toxicity induced INS-1 cells

ROS increased in the STZ-treated group compared to the control group. There was no change in ROS level as a result of DB implementation. ROS increased over time with DB administration after being given STZ compared to control groups. In the group given STZ after DB administration, the level of ROS increased as a result of long-term incubation (Fig. 3).

INS1, INS2 and GLUT2 gene expression increases while IR gene expression decreases with Dinutuximab beta application to toxicity induced INS-1 cells

INS1 and *INS2* gene expression levels increased in the STZ-treated group compared to the control group. *INS1* and *INS2* gene expression levels more decreased with DB administration after given STZ according to given STZ after DB administration. While this expression level increased in given DB after STZ at 48 hours, it was further decreased in given STZ after DB administration. At 72 hours, *INS1* and *INS2* gene expression levels increased with DB administration after being given STZ. In the group given STZ after DB administration, *INS1* and *INS2* gene expression levels increased at 72 hours compared to 48 hours but decreased compared to the control group.

IR gene expression levels decreased at 24 and 72 hours with DB application. Expression levels of this gene decreased in the DB treatment group after STZ administration at 24, 48, and 72 hours. A decrease was observed only in the 48th hour in the group in which STZ was administered after DB administration.

GLUT2 gene expression level decreased with STZ application. An increase was observed at 48. hours of DB administration in *GLUT2* gene expression levels. *GLUT2* gene expression decreased with given DB after STZ administration at the 24th hour, while the expression of this gene increased at the 48th and 72nd hours. In the group given STZ after DB administration, *GLUT2* gene expression increased at the 24th hour and decreased at the 48th hour (Fig. 4).

Discussion

Treatment with antibodies targeting the disialoganglioside GD2 antigen, which is found at high levels in neuroblastoma patients, increased the survival rates of patients with high-risk neuroblastoma [18–20]. Dinutuximab beta is an antibody that also binds to GD2. Its effect on pancreatic tumors is unknown.

The anti-GD2 antibody, dinutuximab beta, recruit neutrophils and natural killer (NK) cells to mediate antibody-dependent cellular cytotoxicity (ADCC) [21–23]. In other words, the anti-GD2 antibody shows its effect in relation to cell cytotoxicity. Based on this situation, cell toxicity was created in insulinoma INS-1 cells, which is a pancreatic tumor, in the first place. Then, DB was given to cells with cytotoxicity. In another group, DB was given first and then toxicity was created with STZ. In this way, the effect of DB on pancreatic tumors was investigated.

Immunotherapeutic treatments for pancreatic cancer have not been successful with very few exceptions [24]. This is most likely due to the late diagnosis of pancreatic cancer [25]. In a study, it was shown that Gemcitabine has immunomodulatory properties in pancreatic cancer [26]. Research has been conducted

by developing new chemotherapeutic combinations for pancreatic cancer. Chemotherapy agents such as pomalidomide, oxaliplatin, and zoledronic acid were combined with Gemcitabine and applied to pancreatic cancer cell lines. As a result, combined immunogenic chemotherapy was provided to be more effective [27]. However, the effects of DB on pancreatic cancer are unknown. In this study, conducted for the first time by us, it was shown that when DB is applied to a pancreatic beta cell tumor, it causes the cells to proliferate. However, if DB is administered after toxicity has been induced with STZ, the cells die depending on time. Conversely, when toxicity is induced with STZ after applying DB to the cells, the cells do not die in the same way. This confirmed that previously known DB acts in cytotoxic conditions and showed that it has important survival effects on pancreatic cancer. While DB causes significant death in toxic conditions, in the case of STZ given after DB, the continuation of cell viability occurred, which is thought to be caused by different mechanisms. In other words, the difference between the proteins which active or inactive of DB after toxicity occurs with STZ, and the proteins that are active or inactive in given DB before toxicity occurs later may be the reason for this situation that different cell viability rate.

Cancer cells die with different types of death, such as necrosis, apoptosis, necroptosis, pyroptosis, or ferroptosis, depending on the stimulation or inhibition of anti-cancer immunity [28–30]. Apoptosis is crucial for regulating cell populations during tissue development and the cell cycle. In addition, cytotoxic T lymphocytes induce cell death in target cells or infected cells [31]. Anti-GD2 monoclonal antibodies target GD2-expressing tumor cells. It causes phagocytosis with antibody-dependent cell-mediated cytotoxicity. Complement-dependent cytotoxicity also causes lysis of the cell. It induces cell death, which leads to apoptosis and necrosis [32]. Anti-GD2 mAbs can induce apoptotic and necrotic cell death in GD2-positive tumor cells without the involvement of immune mechanisms [33, 34]. In this study, cell death occurred depending on time as a result of DB applied after cytotoxicity of the pancreatic beta-cell tumor. While this cell death was more apoptotic cell death at 24 h, cell death increased at 48 h and apoptotic cell death decreased. At the 72 h, while the maximum cell death was observed, apoptotic cell death was not observed. Cell death was not observed when cytotoxicity was induced in cells after DB application.

ROS is formed as a product of oxygen metabolism. Cell signaling and homeostasis also play an important role [35]. Certain levels of ROS promote cell proliferation and cell survival, while too high levels damage cells and cell components. In this way, lipid peroxidation and DNA damage increase, and the cell dies by apoptosis [36]. According to our results, ROS levels increased as cell damage increased. In the results, ROS and apoptotic cell death did not progress in parallel. The ROS level is highest in cases where apoptotic cell death is not observed but cell viability decreases the most. In this case, we can say that the change in the cells after cytotoxicity interacts with the applied DB, on the contrary when DB is applied first and then cytotoxicity is created, there is no such effect.

In our previous study, we observed that *INS1* and *INS2* gene expressions decreased, *IR* gene expression did not change, and *GLUT2* gene expression increased in the group in which apoptotic cell death occurred as a result of exogenously administered substances in insulinoma cells [37]. In this study, similar to the other study, we observed that *INS1* and *INS2* gene expressions were decreased in the group with apoptotic cell death in which DB was applied for 24 hours after cytotoxicity. However, we see that *INS1* and *INS2*

gene expressions increase with increased cell death at 48 and 72 hours, but decreased apoptosis may indicate that there should be another cell death mechanism. Therefore, since cell damage does not occur in apoptotic cell death, the expression of related genes decreases with decreasing cell viability. However, in cases where there is cell damage, it can be thought that it is desirable to increase insulin production, which is very important and typical especially for pancreatic beta cells, in order to protect the remaining cells [38]. Likewise, since there was no cell damage in the group in which cellular cytotoxicity was formed after DB administration, the expression of the relevant genes decreased due to the decreased cell viability. The level of IR gene expression was also decreased in both groups in which DB was given after and before, depending on the death of the cells and the decrease in their viability. Glucose will be taken into the cell via GLUT2. According to the results of the study, increased *GLUT2* gene expression may have caused excessive glucose entry into the cell. This means more insulin secretion from the cell. Therefore, the change in *INS1* and *INS2* gene expressions and the change in *GLUT2* gene expression are in the same direction.

This study, which was performed for the first time in pancreatic beta cells, showed that DB can be effective in pancreatic tumors. However, with further analyzes, it will be possible to elucidate the molecular mechanism of DB by examining its interactions with proteins in the cell.

Declarations

Acknowledgments

The authors would like to thank to Prof. Dr. Claes B. Wollheim (University Medical Center, Geneva) for providing kind gift of insulinoma INS-1 cell lines.

The authors would like to thank to EUSA Pharma for providing kind gift of Dinutuximab beta (Qarziba®), Thank to Dear Raf Vrints for the transfer process of Dinutuximab beta (Qarziba®).

Funding

This work was supported by Scientific Research Project Coordination Unit of Istanbul University. Project No: 34960.

Conflict of interest: The authors declare no conflicts of interest.

Ethics approval: Not applicable.

Consent to participate: Not applicable.

Consent for publication: All authors consent to the publication of this work.

Author Contributions

Ayşe Karatug Kacar¹, created main idea, experimental design, all cell culture experiments done, determination of cell viability, ROS levels and gene expression by qRT-PCR, evaluation of all experimental results, done statistics, written manuscript.

Zelal Adiguzel², determination of cell death detection, ROS levels and gene expression by qRT-PCR, edited manuscript.

References

1. Jansen TJP, van Lith SAM, Boss M, et al. Exendin-4 analogs in insulinoma theranostics. *J Label Compd Radiopharm*. 2019;62:656–672.
2. Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. *Theranostics*. 2020;10:437–461.
3. Poitout V, Olson LK, Robertson RP. Insulin-secreting cell lines: classification, characteristics and potential applications. *Diabetes Metab*. 1996;22(1):7–14.
4. Skelin M, Rupnik M, Cencic A. Pancreatic beta cell lines and their applications in diabetes mellitus research. *ALTEX*. 2010;27(2):105–113.
5. Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. *Expert Review of Anticancer therapy*. 2017;17(10):889–904.
6. Agency EM. Qarziba (dinutuximab beta) summary of product characteristics 2021, https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-productinformation_en.pdf. 2021.
7. Ladenstein RL. Randomization of dose-reduced subcutaneous interleukin-2 (sclL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) longterm infusion (LTI) in front-line high-risk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. *Journal of Clinical Oncology*. 2019;37(15).
8. Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. *Sci Transl Med*. 2018;10.
9. Casey DL, Cheung N-KV. Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on anti-bodies. *Cancer Immunol Res*. 2020;8:161e6.
10. Tarek N, Le Luduec JB, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. *J Clin Invest*. 2012;122:3260e70.
11. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. *Cancer Immunol Immunother*. 2000;48:603e12.
12. Wienke J, Dierselhuys MP, Tytgat GAM, Kunkele A, Nierkens S, Molenaar JJ. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. *European journal of cancer*. 2021;144(Suppl A):123–150.

13. Furman BL. Streptozotocin-induced diabetic models in mice and rats. *Curr Protoc Pharmacol*. 2015;70.
14. Marasco MR, Conteh AM, Reissaus CA, et al. Interleukin-6 reduces β -cell oxidative stress by linking autophagy with the antioxidant response. *Diabetes*. 2018;67(8):1576–1588.
15. Yu L, Li X, Zhang Z, et al. Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic β -cell loss. *Diabetes Obes Metabol*. 2019;21(5):1209–1222.
16. King AJ. The use of animal models in diabetes research. *Br J Pharmacol*. 2012;166(3):877–894.
17. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. *Diabetologia*. 2008;51(2):216–226.
18. Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. *J Clin Oncol Off J Am Soc Clin Oncol*. 2012;30:3264–3270.
19. Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2018;19:1617–1629.
20. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. *N Engl J Med*. 2010;363:1324–1334.
21. Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. *Clin Cancer Res Off J Am Assoc Cancer Res*. 1999;5:4259–4263.
22. Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. *Cancer Immunol Immunother Cll*. 2000;48:603–612.
23. Zeng Y. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. *Mol Immunol*. 2005;42:1311–1319.
24. Gong J, Hendifar A, Tuli R, et al. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. *Clin Transl Med*. 2018;7(1):32.
25. Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment. *Am J Pathol*. 2019;189(1):44–57.
26. Gravett AM, Trautwein N, Stevanovic S, Dalglish AG, Copier J. Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells. *Oncoimmunology*. 2018;7(6):e1438107.
27. Smith PL, Yogaratnam Y, Samad M, Kasow S, Dalglish AG. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. *Clinical and Translational Oncology*. 2021;23:110–121.
28. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death Differ*.

- 2018;25:486–541.
29. Fearnhead HO, Vandenabeele P, Vanden Berghe T. How do we fit ferroptosis in the family of regulated cell death? *Cell Death Differ.* 2017;24:1991–1998.
 30. Nagata S, Tanaka M. Programmed cell death and the immune system. *Nat Rev Immunol.* 2017;17:333–340.
 31. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature.* 1974;248:701–702.
 32. Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. *Front Oncol.* 2020;10:1000.
 33. Doronin II, Vishnyakova PA, Kholodenko IV, et al. Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. *BMC Cancer.* 2014;14:295.
 34. Kholodenko IV, Kalinovskiy DV, Doronin II, Deyev SM, Kholodenko RV. Neuroblastoma origin and therapeutic targets for immunotherapy. *J Immunol Res.* 2018;2018:7394268.
 35. Rouhollahi E. Inhibitory effect of *Curcuma purpurascens* Bl. rhizome on HT-29 colon cancer cells through mitochondrial-dependent apoptosis pathway. *BMC Complement Altern Med.* 2015;15:15–27.
 36. Trachootham D, Lu W, Ogasawara MA, Nilsa RDV, Huang P. Redox regulation of cell survival. *Antioxid. Redox Signal.* 2008;10:1343–1374
 37. Karatug Kacar A. Indomethacin decreases insulin secretion by reducing KCa3.1 as a biomarker of pancreatic tumor and causes apoptotic cell death. *J Biochem Mol Toxicol.* 2020;34(7):e22488.
 38. Karatug Kacar A, Bahadori F, Kepekci Tekkeli SE, Topcu G, Bolkent S. Investigation of cell death mechanism and activity of esculetin-loaded PLGA nanoparticles on insulinoma cells in vitro. *J Pharm Pharmacol.* 2020;72(4):592–606.

Figures

Figure 1

The cell viability % of insulinoma INS-1 cells with given STZ, DB, STZ+DB, DB+STZ and their control groups. For STZ: CB %100 ± 0; 1 mM STZ % 74,59 ± 3,779; 2 mM STZ % 62,76 ± 5,310; 4 mM STZ % 41,96 ± 3,013. For 24h DB: C %100 ± 0; 1 mg DB 110,9 ± 2,678; 2,5 mg DB 115,9 ± 4,087; 5 mg DB 124,7 ± 6,329; 10 mg DB 99,00 ± 5,430; for 48h DB: C %100 ± 0; 1 mg DB 121,2 ± 4,320; 2,5 mg DB 126,3 ± 10,77; 5 mg DB 163,8 ± 13,50; 10 mg DB 133,6 ± 6,067; for 72h DB: C %100 ± 0; 1 mg DB 207,4 ± 6,122; 2,5 mg DB 209,6 ± 9,652; 5 mg DB 255,3 ± 17,12; 10 mg DB 129,0 ± 14,54. For 24h CB+C %100 ± 0; STZ+DB 30,70 ± 0,09765; C+CB %100 ± 0; DB+STZ 86,70 ± 4,718; for 48h CB+C %100 ± 0; STZ+DB 17,84 ± 2,360; C+CB %100 ± 0; DB+STZ 86,40 ± 2,567; for 72h CB+C %100 ± 0; STZ+DB 12,10 ± 2,548; C+CB %100 ± 0; DB+STZ 82,76 ± 11,17.

Figure 2

DAPI stained image of insulinoma INS-1 cells after treatment with STZ, DB, STZ+DB, DB+STZ and their control groups.

Figure 3

ROS production of insulinoma INS-1 cells after treatment with STZ, DB, STZ+DB, DB+STZ and their control groups. For STZ: CB $1,000 \pm 5,774e-007$; STZ $1,577 \pm 0,09305$; C (24h) $1,000 \pm 5,774e-007$; DB (24h) $1,030 \pm 0,06473$; C (48h) $1,000 \pm 5,774e-007$; DB (48h) $1,091 \pm 0,08671$; C (72h) $1,000 \pm 5,774e-007$; DB (72h) $1,047 \pm 0,1235$; CB+C (24h) $1,000 \pm 5,774e-007$; STZ+DB (24h) $1,791 \pm 0,05649$; C (24h)+CB $1,000 \pm 5,774e-007$; DB (24h)+STZ $1,172 \pm 0,06823$; CB+C (48h) $1,000 \pm 5,774e-007$; STZ+DB (48h) $6,654 \pm 0,5947$; C (48h)+CB $1,000 \pm 5,774e-007$; DB (48h)+STZ $1,278 \pm 0,1308$; CB+C (72h) $1,000 \pm 5,774e-007$; STZ+DB (72h) $14,79 \pm 1,290$; C (72h)+CB $1,000 \pm 5,774e-007$; DB (72h)+STZ $1,615 \pm 0,09275$.

Figure 4

INS1, INS2, IR and GLUT2 gene expression levels of insulinoma INS-1 cells after treatment with STZ, DB, STZ+DB, DB+STZ and their control groups. **For INS1:** CB $1,000 \pm 2,500e-007$; STZ $1,207 \pm 0,04333$; C (24 h) $1,000 \pm 2,500e-007$; DB (24h) $0,8725 \pm 0,07296$; C (48h) $1,000 \pm 2,500e-007$; DB (48h) $0,9450 \pm 0,05979$; C (72h) $1,000 \pm 2,500e-007$; DB (72h) $0,9125 \pm 0,08509$; CB+C (24h) $1,000 \pm 2,500e-007$; STZ+DB (24h) $0,1575 \pm 0,01931$; C (24h)+CB $1,000 \pm 2,500e-007$; DB (24h)+STZ $0,6175 \pm 0,05121$; CB+C (48h) $1,000 \pm 2,500e-007$; STZ+DB (48h) $14,47 \pm 0,7534$; C (48h)+CB $1,000 \pm 2,500e-007$; DB (48h)+STZ $0,2400 \pm 0,02858$; CB+C (72h) $1,000 \pm 2,500e-007$; STZ+DB (72h) $28,92 \pm 1,871$; C (72h)+CB $1,000 \pm 2,500e-007$; DB (72h)+STZ $0,7975 \pm 0,1606$. **For INS2:** CB $1,000 \pm 2,500e-007$; STZ $1,307; 0,02963$; C (24 h) $1,000 \pm 2,500e-007$; DB (24h) $0,8875 \pm 0,07510$; C (48h) $1,000 \pm 2,500e-007$; DB (48h) $0,8375 \pm 0,06909$; C (72h) $1,000 \pm 2,500e-007$; DB (72h) $0,8675 \pm 0,07857$; CB+C (24h) $1,000 \pm 2,500e-007$; STZ+DB (24h) $0,1375 \pm 0,01652$; C (24h)+CB $1,000 \pm 2,500e-007$; DB (24h)+STZ $0,5900 \pm 0,05307$; CB+C (48h) $1,000 \pm 2,500e-007$; STZ+DB (48h) $15,42 \pm 0,4965$; C (48h)+CB $1,000 \pm 2,500e-007$; DB (48h)+STZ $0,2425 \pm 0,02869$; CB+C (72h) $1,000 \pm 2,500e-007$; STZ+DB (72h) $89,11 \pm 6,170$; C (72h)+CB $1,000 \pm 2,500e-007$; DB (72h)+STZ $0,7375 \pm 0,1352$. **For IR:** CB $1,000 \pm 2,500e-007$; STZ $1,008 \pm 0,1629$; C (24 h) $1,000 \pm 2,500e-007$; DB (24h) $0,7825 \pm 0,04973$; C (48h) $1,000 \pm 2,500e-007$; DB (48h) $1,053 \pm 0,09003$; C (72h) $1,000 \pm 2,500e-007$; DB (72h) $0,7300 \pm 0,04813$; CB+C (24h) $1,000 \pm 2,500e-007$; STZ+DB (24h) $0,1725 \pm 0,008539$; C (24h)+CB $1,000 \pm 2,500e-007$; DB (24h)+STZ $1,213 \pm 0,2596$; CB+C (48h) $1,000 \pm 2,500e-007$; STZ+DB (48h) $0,6350 \pm 0,1241$; C (48h)+CB $1,000 \pm 2,500e-007$; DB (48h)+STZ $0,4200 \pm 0,06403$; CB+C (72h) $1,000 \pm 2,500e-007$; STZ+DB (72h) $0,09750 \pm 0,01109$; C (72h)+CB $1,000 \pm 2,500e-007$; DB (72h)+STZ $0,8275 \pm 0,1606$. **For GLUT2:** CB $1,000 \pm 2,500e-007$; STZ $0,4775 \pm 0,04661$; C (24 h) $1,000 \pm 2,500e-007$; DB (24h) $0,9050 \pm 0,05909$; C (48h) $1,000 \pm 2,500e-007$; DB (48h) $1,060 \pm 0,02828$; C (72h) $1,000 \pm 2,500e-007$; DB (72h) $1,040 \pm 0,09695$; CB+C (24h) $1,000 \pm 2,500e-007$; STZ+DB (24h) $0,7125 \pm 0,02689$; C (24h)+CB $1,000 \pm 2,500e-007$; DB (24h)+STZ $1,275 \pm 0,08088$; CB+C (48h) $1,000 \pm 2,500e-007$; STZ+DB (48h) $22,54 \pm 0,2165$; C (48h)+CB $1,000 \pm 2,500e-007$; DB (48h)+STZ $0,4900 \pm 0,06468$; CB+C (72h) $1,000 \pm 2,500e-007$; STZ+DB (72h) $44,22 \pm 4,286$; C (72h)+CB $1,000 \pm 2,500e-007$; DB (72h)+STZ $1,180 \pm 0,2000$.